Clinical trial
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
NCT00466687 · Vanderbilt-Ingram Cancer Center, Other · Completed
Key facts
| NCT number | NCT00466687 |
|---|---|
| Title | Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma |
| Official title | A Phase II Trial of Tarceva (Erlotinib) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Melanoma |
| Lead sponsor | Vanderbilt-Ingram Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological, Drug, Genetic, Other, Procedure |
| Interventions | bevacizumab, erlotinib hydrochloride, fluorescence in situ hybridization, gene expression analysis, immunologic technique, laboratory biomarker analysis, biopsy |
| Enrollment | 34 |
| Start date | Sep 1, 2004 |
| Primary completion | Aug 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Apr 27, 2007 |
| Last update posted | Jul 22, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: